CN117462626A - Traditional Chinese medicine composition for treating skin injury caused by rash - Google Patents
Traditional Chinese medicine composition for treating skin injury caused by rash Download PDFInfo
- Publication number
- CN117462626A CN117462626A CN202311664721.8A CN202311664721A CN117462626A CN 117462626 A CN117462626 A CN 117462626A CN 202311664721 A CN202311664721 A CN 202311664721A CN 117462626 A CN117462626 A CN 117462626A
- Authority
- CN
- China
- Prior art keywords
- parts
- rash
- skin
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010037844 rash Diseases 0.000 title claims abstract description 99
- 208000010201 Exanthema Diseases 0.000 title claims abstract description 96
- 201000005884 exanthem Diseases 0.000 title claims abstract description 96
- 239000003814 drug Substances 0.000 title claims abstract description 80
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 208000028990 Skin injury Diseases 0.000 title claims abstract description 15
- 231100000046 skin rash Toxicity 0.000 claims abstract description 31
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 22
- 201000005202 lung cancer Diseases 0.000 claims abstract description 22
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 22
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 16
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 16
- 241000219304 Portulacaceae Species 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 241001071917 Lithospermum Species 0.000 claims abstract description 14
- 229940037003 alum Drugs 0.000 claims abstract description 14
- 241001313857 Bletilla striata Species 0.000 claims abstract description 13
- 239000006210 lotion Substances 0.000 claims abstract description 11
- 206010040840 Skin erosion Diseases 0.000 claims abstract description 8
- 239000003053 toxin Substances 0.000 claims abstract description 8
- 231100000765 toxin Toxicity 0.000 claims abstract description 8
- 206010020880 Hypertrophy Diseases 0.000 claims abstract description 7
- 230000009545 invasion Effects 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims description 18
- 206010067484 Adverse reaction Diseases 0.000 claims description 14
- 230000006838 adverse reaction Effects 0.000 claims description 14
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 9
- 206010024438 Lichenification Diseases 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 206010040882 skin lesion Diseases 0.000 claims description 7
- 231100000444 skin lesion Toxicity 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000008447 perception Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000007012 clinical effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 24
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 208000003251 Pruritus Diseases 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 12
- 101150039808 Egfr gene Proteins 0.000 description 11
- 230000007803 itching Effects 0.000 description 9
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 229940126680 traditional chinese medicines Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 208000001848 dysentery Diseases 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010040925 Skin striae Diseases 0.000 description 3
- 206010059516 Skin toxicity Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 231100000438 skin toxicity Toxicity 0.000 description 3
- 235000019614 sour taste Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 240000001949 Taraxacum officinale Species 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000008589 Cortex Fraxini Substances 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000000774 Cunila origanoides Species 0.000 description 1
- 235000018274 Cunila origanoides Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 235000014866 Dictamnus albus Nutrition 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 240000003915 Lophatherum gracile Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 240000004064 Poterium sanguisorba Species 0.000 description 1
- 235000008291 Poterium sanguisorba Nutrition 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241000123887 Pulsatilla chinensis Species 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 description 1
- 241001180876 Saposhnikovia Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229950007440 icotinib Drugs 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
- 201000000966 lung oat cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000720 neurosecretory effect Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- -1 rhizoma anemarrhenae Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and in particular relates to a traditional Chinese medicine composition for treating skin rash and skin injury caused by the rash, wherein the rash is skin rash which is generated by diagnosing lung cancer and receiving EGFRIS medicine treatment, the skin injury reaches skin erosion, exudation, hypertrophy and moss appearance which are generated by rash of 2 minutes or more, and the rash is mainly caused by insufficient endowment of a patient, invasion of wind, heat and damp evil, special toxin of the medicine and internal and external combination of evil. The traditional Chinese medicine composition provided by the invention comprises the following components: 30-50 parts of honeysuckle, 30-50 parts of purslane, 30-50 parts of radix sophorae flavescentis, 30-50 parts of cortex dictamni, 20-40 parts of radix scutellariae, 20-40 parts of lithospermum, 20-40 parts of radix sileris, 10-20 parts of dried alum, 20-40 parts of bletilla striata and 20-50 parts of radix sanguisorbae. Clinical practice shows that the honeysuckle flower and astragalus root lotion has good clinical effect on treating the severe rash.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating rash and skin injury caused by the rash.
Background
Lung cancer is the malignant tumor with highest global morbidity and mortality, and is classified into two major classes, small cell lung cancer and non-small cell lung cancer (non-small cell lung cancer, NSCLC) according to histopathological classification. Malignant tumors in Chinese residents are first in the death rate of various diseases, the incidence rate and death rate of lung cancer are the first, the total number of new lung cancer cases in China every year is 73.3 ten thousand, the death number is about 61 ten thousand, non-small cell lung cancer (NSCLC) accounts for about 80-85% of the total number, squamous cell carcinoma (squamous cell carcinoma), adenocarcinoma and large cell carcinoma, about 75% of patients have been found to be locally advanced or metastatic diseases, the survival rate of 5 years is very low, the survival rate of squamous cell lung cancer accounts for 29% of lung cancer, and the lung cancer also starts from large bronchi, but the growth is slower. The size of these tumors varies in diagnosis. Adenocarcinomas are the most common subtype of NSCLC, accounting for 32% of lung cancer, which is a form that begins near the gas exchange surface of the lung. Most cases of adenocarcinoma are associated with smoking, however, in humans who never smoke, adenocarcinoma is the most common form of lung cancer. Subtypes of adenocarcinoma, bronchioloalveolar carcinoma, are more common in female non-smokers and may have different responses to treatment. Large cell carcinoma is a rapidly growing form, 9% of lung cancer, which grows near the surface of the lung. Small cell lung cancer (SCLC, also known as "oat cell carcinoma") is a rare form of lung cancer. It tends to start with a large breathing tube and grow rapidly to become very large. The "oat" cells contain dense neurosecretory particles, which lead to this endocrine/paraneoplastic syndrome combination. It is initially more sensitive to chemotherapy, but eventually leads to a poor prognosis and is often metastatic in appearance.
The epidermal growth factor receptor inhibitors (epidermal growth factor receptor inhibitors, EGFRs) are important means for treating lung cancer at present due to outstanding curative effects in treating malignant tumors such as non-small cell lung cancer, colorectal cancer and the like, and have a plurality of clinical applications at present, but the adverse reactions accompanied by the inhibitors bring great trouble to patients who receive treatment. EGFR directs proliferation, adhesion, migration, differentiation and apoptosis of cells, and is closely related to the formation and deterioration of tumor cells such as lung cancer, breast cancer, and prostate cancer. The earliest and highest incidence of EGFRs related rash in EGFRs related skin adverse reactions has great influence on various aspects of image, social contact, quality of life and the like of patients, and even causes that part of patients have to stop receiving EGFRs treatment, thereby influencing the survival time of the patients. It is currently believed that the occurrence of EGFRIs-related rashes is related to mechanisms such as cytokine-mediated inflammatory responses, and thus clinical guidelines recommend the use of antibiotics and hormones to treat rashes, but the efficacy is unsatisfactory, and antibiotics and hormones are also associated with insignificant side effects.
The rash associated with EGFRs belongs to the category of "drug toxicity" in traditional Chinese medicine. The "the theory of disease sources, sore diseases, sore on the head and face and body" considers that the lung governs qi and is in the fur; the spleen governs the muscles. Skin striae are broken due to qi deficiency, which is the cause of rheumatism; internal heat causes spleen qi to warm and spleen air temperature causes muscle to generate heat. The heat and dampness are combined to promote the generation of sores on the head, face and body, which means that the rash is located in the lung and related to the spleen and stomach, and wind, damp and heat are three pathological factors. The rash caused by EGFRs is mostly caused by insufficient endowment of the patient with factors, invasion of wind, heat and dampness, special toxin of the sensitive medicine and internal and external pathogenic factors combined by combining the characteristics of the literature and clinical manifestations. The traditional Chinese medicine intervention can obviously relieve the grading of the toxic reaction of the skin related to the EGFRs, obviously relieve the symptoms of traditional Chinese medicine in patients, improve the life quality of the patients, and does not influence the anti-tumor curative effect of the EGFRs.
In Chinese patent CN107617010B, a traditional Chinese medicine composition for treating rash for external use, a preparation method and application thereof are disclosed, wherein the traditional Chinese medicine composition comprises the following traditional Chinese medicines: the formula of the baikal skullcap root, purslane, cortex dictamni, kuh-seng and dandelion is used for treating the rash related to the EGFRIs, but other symptoms of the rash related to the EGFRIs, such as itching, bleeding, pain and the like, which occur in the repairing process are ignored, so that broad-spectrum treatment cannot be realized. As another example, in chinese patent CN101810799B, a traditional Chinese medicine composition for treating eruption and a preparation method thereof are disclosed, the traditional Chinese medicine composition is composed of the following traditional Chinese medicines: herba schizonepetae, radix sileris, fructus forsythiae, dandelion, mint, fructus arctii, periostracum cicadae, fermented soybean, radix puerariae, radix bupleuri, folium mori, chrysanthemum, gypsum, rhizoma anemarrhenae, radix trichosanthis, lophatherum gracile, radix scutellariae, cortex dictamni, radix sophorae flavescentis, cortex fraxini, radix rehmanniae, radix scrophulariae, cortex moutan, lithospermum, honeysuckle, bunge corydalis herb, indigo naturalis, herba houttuyniae, purslane, pulsatilla chinensis, rhizoma smilacis glabrae, cortex lycii radicis, semen pruni, rheum officinale, angelica sinensis, radix paeoniae alba, radix astragali, gardenia, selfheal, reed rhizome and the like are complex in formula, and the problems of itching and the like in the repairing process are also ignored. The invention is based on the traditional Chinese medicine formula disclosed in Chinese patent CN107617010B, and the traditional Chinese medicine composition is added on the basis of the traditional Chinese medicine formula, so that the special medicine composition not only can treat the rash related to EGFRs, but also can take care of the problems in repairing, and has reasonable formula compatibility and obvious effect.
The theory of external treatment, i.e. the theory of internal treatment, the recipe of external treatment, i.e. the recipe of internal treatment, is called "Li parallel text". As can be seen from the above, the external treatment is based on the theory of internal treatment, and the external treatment can also have the efficacy of internal treatment. For EGFR-TKIs related rash, the external medicine can directly permeate skin and skin striae and striae of the body surface, and can reach meridians and collaterals to reach viscera and disease places, thereby regulating qi and blood and yin-yang balance of the organism to exert curative effect.
Disclosure of Invention
In a first aspect, the invention provides a traditional Chinese medicine composition for treating skin rash and skin injury caused by skin rash, wherein the skin rash is skin rash which is caused by lung cancer diagnosis and EGFRIS drug treatment, the skin injury reaches skin erosion, exudation, hypertrophy and lichenification which are caused by skin rash of 2 minutes or more, the skin rash is mainly caused by insufficient essence intrinsic endowment, wind, heat and damp invasion of patients, and special toxin of sensitive drugs, and the internal and external evils, and the traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: 30-50 parts of honeysuckle, 30-50 parts of purslane, 30-50 parts of radix sophorae flavescentis, 30-50 parts of cortex dictamni, 20-40 parts of radix scutellariae, 20-40 parts of lithospermum, 20-40 parts of radix sileris, 10-20 parts of dried alum, 20-40 parts of bletilla striata and 20-50 parts of radix sanguisorbae.
The scoring criteria for skin lesions are shown in the following table:
further, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 35-45 parts of honeysuckle, 35-45 parts of purslane, 35-45 parts of radix sophorae flavescentis, 35-45 parts of cortex dictamni, 25-35 parts of radix scutellariae, 25-35 parts of lithospermum, 25-35 parts of radix sileris, 10-15 parts of dried alum, 25-35 parts of bletilla striata and 25-40 parts of radix sanguisorbae.
Further, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 40 parts of honeysuckle, 40 parts of purslane, 40 parts of radix sophorae flavescentis, 40 parts of cortex dictamni, 30 parts of radix scutellariae, 30 parts of lithospermum, 30 parts of radix saposhnikoviae, 15 parts of dried alum, 30 parts of bletilla striata and 40 parts of radix sanguisorbae.
Further, the lung cancer may be classified into small cell lung cancer and non-small cell lung cancer.
In a second aspect, the invention provides a traditional Chinese medicine composition preparation for treating skin rash and skin injury caused by the skin rash, wherein the skin rash is skin rash which is caused by lung cancer diagnosis and EGFRIS medicine treatment, the skin injury reaches skin erosion, exudation, hypertrophy and lichenification which are caused by the skin rash of 2 minutes or more, the traditional Chinese medicine preparation can comprise a traditional Chinese medicine composition capable of treating the skin rash and pharmaceutically acceptable auxiliary materials, and the traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: 30-50 parts of honeysuckle, 30-50 parts of purslane, 30-50 parts of radix sophorae flavescentis, 30-50 parts of cortex dictamni, 20-40 parts of radix scutellariae, 20-40 parts of lithospermum, 20-40 parts of radix sileris, 10-20 parts of dried alum, 20-40 parts of bletilla striata and 20-50 parts of radix sanguisorbae.
Further, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 35-45 parts of honeysuckle, 35-45 parts of purslane, 35-45 parts of radix sophorae flavescentis, 35-45 parts of cortex dictamni, 25-35 parts of radix scutellariae, 25-35 parts of lithospermum, 25-35 parts of radix sileris, 10-15 parts of dried alum, 25-35 parts of bletilla striata and 25-40 parts of radix sanguisorbae.
Further, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 40 parts of honeysuckle, 40 parts of purslane, 40 parts of radix sophorae flavescentis, 40 parts of cortex dictamni, 30 parts of radix scutellariae, 30 parts of lithospermum, 30 parts of radix saposhnikoviae, 15 parts of dried alum, 30 parts of bletilla striata and 40 parts of radix sanguisorbae.
Further, the auxiliary materials are medicinal auxiliary materials which have enhanced curative effects on the main medicines.
Further, the preparation of the traditional Chinese medicine composition can be patches, cataplasm, ointment, plaster, gel, liniment, lotion, film coating agent and the like.
In one embodiment, the formulation of the traditional Chinese medicine composition is selected from lotions.
In a third aspect, the present invention provides an application of the Chinese medicinal composition according to the first aspect in preparing a preparation for treating rash, wherein the rash is mainly caused by insufficient endowment of a patient, invasion of wind, heat and dampness evil, and special toxin of a sensitive medicament.
The medicine properties and effects of the traditional Chinese medicinal materials are as follows:
honeysuckle flower: sweet in flavor, cold in nature, enters lung, heart and stomach meridians, and clears away heat and toxic materials, and dispels wind-heat. Can be used for treating carbuncle, furuncle, pharyngitis, erysipelas, dysentery with blood, wind-heat type common cold, and epidemic febrile disease.
Purslane: sour taste, cold nature, liver and large intestine meridians, heat and toxic materials clearing away, blood cooling and hemostasis, dysentery stopping. Can be used for treating dysentery with heat toxin, carbuncle, furuncle, eczema, erysipelas, snake and insect bite, hematochezia, hemorrhoid, metrorrhagia, and hemorrhage.
Radix Sophorae Flavescentis: bitter taste, cold nature, heart, liver, stomach, large intestine and bladder meridian, heat-clearing and dampness-eliminating, insecticidal and diuretic. Can be used for treating dysentery, hematochezia, jaundice, uroschesis, leucorrhea with reddish discharge, pudendum swelling, pruritus vulvae, eczema, skin pruritus, and scabies; it is used for treating trichomonas vaginitis.
Radix Scutellariae Baicalensis: bitter taste, cold property, lung, gallbladder, spleen, large intestine and small intestine channels, heat clearing, dampness eliminating, fire purging, toxin removing, hemostasis and miscarriage prevention. Can be used for treating damp-heat, summer-heat, chest distress, emesis, damp-heat distention and fullness, dysentery, jaundice, cough due to lung heat, polydipsia due to high fever, hematemesis, epistaxis, carbuncle, swelling, sore, and fetal movement.
Radix Arnebiae: sweet and salty in flavor, cold in nature, good in property of inducing heart and liver meridians, clearing heat and cooling blood, promoting blood circulation and removing toxicity, promoting eruption and removing spots. Can be used for treating excessive heat and toxic materials, macula, purple black, measles, skin infection, eczema, and scald due to fire and water.
Radix Sanguisorbae: bitter, sour and astringent taste, slightly cold nature, good liver and large intestine meridians, blood cooling and hemostasis, detoxification and sore healing. Can be used for treating hematochezia, hemorrhoid, bloody dysentery, metrorrhagia, scald due to fire and water, carbuncle, and skin sore.
Cortex Dictamni Radicis: bitter taste, cold nature, spleen, stomach and bladder meridians entered, heat-clearing and dampness-drying, wind-dispelling and detoxifying. Can be used for treating sore due to damp-heat, yellow Shui Linli, eczema, rubella, scabies, arthralgia due to wind-damp-heat, jaundice, and dark urine.
Wind prevention: pungent and sweet in flavor, slightly warm in nature, enter bladder, liver and spleen meridians, dispel wind, relieve exterior syndrome, dispel dampness, alleviate pain and stop spasm. Can be used for treating common cold, headache, rheumatalgia, rubella, pruritus, and tetanus.
Drying alum: sour and astringent taste, cold nature, and good property of inducing menstruation in lung, spleen, liver and large intestine, astringing dampness and healing sore, stopping bleeding and resolving putrefaction. Can be used for treating eczema, wet sore, rectocele, hemorrhoid, purulent ear, pudendum itch, epistaxis, and meat.
Bletilla striata: bitter, sweet and astringent in flavor, slightly cold in nature. It can be used for treating pulmonary, hepatic and gastric menstruation, astringing, stopping bleeding, relieving swelling, and promoting granulation. Can be used for treating hemoptysis, hematemesis, traumatic hemorrhage, pyocutaneous disease, toxic swelling, and chapped skin.
The invention takes dittany bark and kuh-seng as principal drugs to remove dampness and heat, and aims at the root of the disease, and is matched with baikal skullcap root, honeysuckle, purslane, garden burnet root and lithospermum to clear away heat and toxic materials and cool blood, and strengthens the function of the principal drugs to remove dampness, and the divaricate saposhnikovia root, dried alum and bletilla tuber are matched with principal drugs to play roles of dispelling wind and relieving itching, astringing dampness and healing sore and improving symptoms.
Drawings
Figure 1 40 patients were graded for rash before and after treatment.
Detailed Description
The following describes the invention in more detail. The description of these embodiments is provided to assist understanding of the present invention, but is not intended to limit the present invention. In addition, the technical features of the embodiments described below may be combined with each other as long as they do not collide with each other.
The experimental methods in the following examples, unless otherwise specified, are conventional, and the experimental materials used in the following examples, unless otherwise specified, are commercially available.
Example 1
Study object: patients with established bronchopulmonary carcinoma and treated with EGFRIS drugs developed skin erosion, exudation, hypertrophy and lichenification.
The diagnosis of lung cancer is based on: lung cancer diagnostic criteria: refer to WHO chest tumor classification (fifth edition): 2021; chinese clinical oncology society, diagnosis and treatment guide for non-small cell lung cancer 2023, people health Press 2023.
Diagnostic criteria for EGFRIs-related rashes: 1. patients received EGFRIs treatment; 2. rash appears after administration; 3. rashes appear as acneiform or pustular and are distributed in the areas of sebaceous gland hyperactivity with itching.
Diagnostic criteria for traditional Chinese medicine: diagnostic criteria in TCM for EGFRIs related rashes: wind-heat type: acne-like rash is accompanied by itching, reddish complexion, reddish eyes, pale red or red tongue. Damp-heat type: pustular rash with bitter taste, yellow urine, red tongue and yellow coating.
Condition of selection:
grading application of EGFR related rash after diagnosis of bronchopulmonary carcinoma and EGFR related rash after treatment with EGFR drugs, the grading standard of EGFR related adverse skin reaction MASCC formulated by the national institute of cancer support therapy (multinational association ofsupportive care in cancer, MASCC).
Exclusion conditions:
1. concurrent with other skin diseases, allergic patients to traditional Chinese medicines used in the project, the treatment of EGFRIS is stopped, and the classification of rash MASCC is grade 1.
2. The severity of adverse skin reactions is below grade 4 according to the common adverse reaction event evaluation criteria (CTCAE) version 5.0 established by the U.S. department of health and public service, national institutes of health, and national cancer institute.
The research method comprises the following steps:
the invention relates to a traditional Chinese medicine lotion formula:
30 parts of honeysuckle, 30 parts of purslane, 30 parts of radix sophorae flavescentis, 20 parts of radix scutellariae, 20 parts of lithospermum, 20 parts of radix sanguisorbae, 30 parts of cortex dictamni, 20 parts of radix saposhnikoviae, 10 parts of dried alum and 20 parts of bletilla striata.
The application method of the traditional Chinese medicine lotion comprises the following steps: the traditional Chinese medicine is decocted with 1000 ml of water for 30 minutes, the traditional Chinese medicine liquid is reserved with 500 ml, the non-woven fabric is soaked in the medicine liquid and then is externally applied to the skin erosion, hypertrophy and lichenification, if the rash is sporadic or is not suitable for external application locally, the medicine liquid can be directly applied to the rash, if the area of the rash is wide, the medicine amount can be properly increased, and a medicine bath mode is adopted for increasing the medicine liquid. After use, the medicine is washed with clean water for 30 minutes twice a day to avoid pigmentation caused by the residue of the Chinese medicine liquid, and is continuously applied for 14 days.
Observation follow-up: when the patient is in the group, the patient is subjected to detailed inquiry and physical examination, and the original medical record is recorded. Rashes of patients enrolled in the group were graded according to the MASCC standard. Patients were followed at day 7 and day 14 of the group, and rashes were reclassified according to MASCC criteria.
The main observation indexes are as follows:
changes in rash grading before and after treatment: grading of EGFRIs-related rash EGFRIs-related skin adverse reaction MASCC grading criteria, formulated by the cancer support therapy multinational institute (multinational association ofsupportive care in cancer, MASCC), are shown in table 1.
TABLE 1 EGFRIS-related rash grading criteria
Note that: the distance between rashes is more than or equal to 2cm, which is 2 points
Secondary observations: referring to the guidelines of clinical research on new traditional Chinese medicines, the quantitative scoring changes of the symptoms of the wet sore of the traditional Chinese medicine before and after treatment. Total score = itching degree score + rash face score + rash morphology score, see table 2.
TABLE 2 quantitative Table of skin adverse reaction symptoms
Note that: 1 the rash scores add up if polymorphic lesions. 2 skin area burn palmar measurement: each palm area is a scoring unit, and less than one palm area is calculated in half of the scoring unit. The area of skin lesions was calculated using the PASI scoring system.
Curative effect judgment criteria:
the treatment efficiency of the EGFRs related moderate and severe rash. Patient efficacy evaluation is performed according to efficacy evaluation criteria established by the U.S. EGFRIS-related skin toxicity seminar consensus, and efficacy is classified into three categories of cure, improvement and invalidation.
And (3) healing: namely, the skin adverse reaction of the patient to be evaluated disappears, no subjective symptoms and no infection symptoms are caused, and the life and work can be normally carried out.
Improvement: namely, the rated skin adverse reaction of the patient is reduced by one stage or more, or the skin adverse reaction distribution of the patient is changed into local form widely, subjective symptoms of the patient are reduced or eliminated, and the quality of life score of the patient is obviously improved earlier.
Invalidation: the skin adverse reaction of the patient is evaluated to be unchanged compared with the skin adverse reaction before treatment, or the skin adverse reaction grading is improved, or the skin adverse reaction distribution of the patient is changed from local to systemic distribution, the patient has new subjective symptoms or the original subjective symptoms are aggravated, and the life quality of the patient is obviously deteriorated.
Total effective rate of treatment: i.e. the post-treatment efficacy is evaluated as the sum of the number of cases of recovery and improvement, accounting for the percentage of the total number of cases of the group, i.e. total effective rate = (recovery + improvement)/total number of cases x100%.
Symptom quantification data scoring criteria: and calculating the treatment efficiency according to the quantitative scoring change of the skin damage pruritus degree, distribution and morphology. Therapeutic efficiency calculation formula (nimodipine method): [ (pre-treatment score-post-treatment score)/pre-treatment score ] ×100%.
And (3) healing: the skin damage is completely resolved, the local symptoms disappear, and the score is reduced by more than or equal to 95% before and after treatment;
the effect is shown: most of skin damage is resolved, local symptoms are obviously improved, and scores are reduced by less than 95% before and after treatment by 70%;
the method is effective: partial skin damage is resolved, local symptoms are improved, and scores are reduced by less than 70% before and after treatment;
invalidation: there is no improvement or increase in skin lesions, no improvement or aggravation of local symptoms, and a decrease in score of < 30% before and after treatment.
Study results:
a total of 40 lung adenocarcinoma patients in the group, wherein 16 men and 24 women; the average age was 63.2 years (+ -11.6 years), and all patients used 7 EGFRIS drugs (including gefitinib, erlotinib, icotinib, ametinib, octenib, afatinib, dacatinib). All patients are given 2 weeks of external treatment with traditional Chinese medicines, and the treatment effects are as follows:
the treatment effect evaluation of the American EGFRs related skin toxicity workshop consensus standard shows that 7 cases are healed, 24 cases are improved, 9 cases are not effective, and the total effective rate is 77.5%. The grading of rash of patients before and after treatment is shown in FIG. 1.
Evaluation of efficacy of symptom quantification data scoring criteria: 9 cases are cured, 4 cases are obvious, 24 cases are effective, 3 cases are ineffective, and the total effective rate is 92.5%. The mean value of the pre-treatment symptom scores is 6.23 (+ -1.72), the mean value of the post-treatment scores is 2.45 (+ -1.76), the average symptom improvement rate is 60.7%, the symptom scores of the patients before and after treatment are shown in table 3, and the curative effect data of different skin lesions are shown in table 4.
TABLE 3 distribution of patient symptom scores before and after treatment
TABLE 4 therapeutic efficacy data for different skin lesions types
In the process of analyzing the clinical treatment effect of the prescription, the prescription is found to have more prominent treatment effect on the rash which is characterized by erosion and exudation. And (3) data display: the local rash is manifested by 13 patients suffering from erosion exudation or even suppuration, the score is reduced by 5.08 minutes before and after treatment, the exudation and the erosion wound are all improved or even eliminated, and the pain is also obviously improved. The average score reduction before and after treatment of the other 27 cases was 3.15, and the two had statistical differences (P < 0.05), indicating that the composition had better treatment effect on exudation and erosion-based skin changes than acne skin changes manifested as a single papule or pustule.
The literature reports that the treatment effective rate of EGFR related rash is 55.56% by adopting Western medicine treatment scheme (clinical practice guidelines for EGFR related skin toxicity: the external hydrocortisone cream for patients with moderate rash is orally taken simultaneously with minocycline, and the external hydrocortisone cream for patients with severe rash is orally taken in combination with minocycline.
The external treatment of the traditional Chinese medicine lotion has good clinical curative effect. No obvious adverse reaction occurs in the external treatment process of the traditional Chinese medicine of all patients, and only two patients react the odor of the medicine to be bad.
Typical cases:
typical case 1: men, 35 years old, 2023, 3 months and 21 days visit, patients diagnosed with lung adenocarcinoma, lymph node metastasis, bone metastasis, pericardium metastasis, double lung metastasis, EGFR 19-DEL, failure of first line targeted drug therapy, small cell transformation after second line anti-vascular immunotherapy, double lung cancer lymphangitis after 2-cycle CE regimen chemotherapy, mediastinum and cervical lymph node radiotherapy. When the dacatinib is taken for treatment, dense rash of the head and the face occurs after 2 weeks of administration, suppurative folliculitis is accompanied, and meanwhile, a plurality of rash of the trunk part is classified as 2 minutes, and after the lotion (prepared in example 1) is adopted for external treatment for 2 weeks, the rash classification is reduced to 2 minutes. Although the rash area is not obviously reduced, the skin redness, swelling and suppuration are obviously improved, the color is darkened, partial desquamation is realized, and the symptoms of itching and pain are obviously improved.
Typical case 2: men, 53 years old, 7 months and 19 days 2022 visit, patients diagnose lung adenocarcinoma, double lung and pleural metastasis in 2021 month, and the condition is stable by using the oxtinib treatment. The skin rash on the chest and back was evident in the treatment, with itching discomfort, the skin rash was evaluated and graded for 3 minutes, the skin rash was significantly reduced, the symptoms were substantially disappeared, and the skin rash was graded for 1 minute after 2 weeks of external application treatment with the lotion of the present invention (prepared in example 1).
Typical case 3: women, 75 years old, 25 days of treatment in 2023, 4 months, patients diagnosed with left lung adenocarcinoma for 1 year, lung portal lymph node metastasis, double lung metastasis, brain metastasis, 45m copies of dactyltinib were treated once daily until now, the disease was stable, the symptoms were seen as scattered throughout the body with itching, the skin rash was classified as 3 minutes with the front chest and back, after 2 weeks of bathing with the lotion of the present invention (prepared in example 1), the symptoms disappeared, and the skin rash was evaluated as healing.
Claims (9)
1. A traditional Chinese medicine composition for treating skin rash and skin injury caused by the rash, wherein the rash is skin rash which is caused by lung cancer diagnosis and EGFRIS drug treatment, the skin injury reaches skin erosion, exudation, hypertrophy and lichenification which occur in the rash of 2 minutes or more, the rash is mainly caused by insufficient endowment of a patient, invasion of wind, heat and damp evil, and special toxin of a drug is sensed, and the skin rash is caused by the internal and external evil combination, and the traditional Chinese medicine composition is prepared from the following traditional Chinese medicine materials in parts by weight: 30-50 parts of honeysuckle, 30-50 parts of purslane, 30-50 parts of radix sophorae flavescentis, 30-50 parts of cortex dictamni, 20-40 parts of radix scutellariae, 20-40 parts of lithospermum, 20-40 parts of radix sileris, 10-20 parts of dried alum, 20-40 parts of bletilla striata and 20-50 parts of radix sanguisorbae.
2. The traditional Chinese medicine composition for treating rash and skin injury caused by rash according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 40 parts of honeysuckle, 40 parts of purslane, 40 parts of radix sophorae flavescentis, 40 parts of cortex dictamni, 30 parts of radix scutellariae, 30 parts of lithospermum, 30 parts of radix saposhnikoviae, 15 parts of dried alum, 30 parts of bletilla striata and 40 parts of radix sanguisorbae.
3. The composition of claim 1, wherein the lung cancer is classified into small cell lung cancer and non-small cell lung cancer.
4. A traditional Chinese medicine composition preparation for treating skin rash and skin injury caused by the skin rash, wherein the skin rash is skin rash which is caused by lung cancer diagnosis and EGFRIS drug treatment, the skin injury reaches skin erosion, exudation, hypertrophy and lichenification which are caused by the skin rash of 2 minutes or more, the traditional Chinese medicine preparation can comprise a traditional Chinese medicine composition capable of treating the skin rash and pharmaceutically acceptable auxiliary materials, and the traditional Chinese medicine composition is prepared from the following traditional Chinese medicine materials in parts by weight: 30-50 parts of honeysuckle, 30-50 parts of purslane, 30-50 parts of radix sophorae flavescentis, 30-50 parts of cortex dictamni, 20-40 parts of radix scutellariae, 20-40 parts of lithospermum, 20-40 parts of radix sileris, 10-20 parts of dried alum, 20-40 parts of bletilla striata and 20-50 parts of radix sanguisorbae.
5. The traditional Chinese medicine composition preparation for treating rash and skin injury caused by rash according to claim 4, wherein the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 40 parts of honeysuckle, 40 parts of purslane, 40 parts of radix sophorae flavescentis, 40 parts of cortex dictamni, 30 parts of radix scutellariae, 30 parts of lithospermum, 30 parts of radix saposhnikoviae, 15 parts of dried alum, 30 parts of bletilla striata and 40 parts of radix sanguisorbae.
6. The formulation of claim 4, wherein the adjuvant is a pharmaceutical adjuvant having enhanced therapeutic effects on the principal drug.
7. The formulation of claim 4, wherein the formulation of the composition is one or more of a patch, a cataplasm, an ointment, a plaster, a gel, a liniment, a lotion and a film coating.
8. The formulation of claim 4, wherein the formulation of the composition is selected from the group consisting of lotions.
9. Use of a Chinese medicinal composition according to any one of claims 1-3 for the preparation of a formulation for the treatment of skin rash and skin lesions caused by rash, said rash being an adverse reaction to skin rash resulting from the definite diagnosis of lung cancer and the receipt of an EGFRIs drug treatment, said skin lesions reaching skin erosion, exudation, hypertrophy and lichenification resulting from rash of 2 minutes or more, said rash being caused by insufficient endowment of the patient with factors such as wind, heat, invasion of damp evil, additional perception of special toxins of the drug, and internal and external combination of evil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311664721.8A CN117462626B (en) | 2023-12-06 | 2023-12-06 | Traditional Chinese medicine composition for treating skin injury caused by rash |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311664721.8A CN117462626B (en) | 2023-12-06 | 2023-12-06 | Traditional Chinese medicine composition for treating skin injury caused by rash |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117462626A true CN117462626A (en) | 2024-01-30 |
| CN117462626B CN117462626B (en) | 2024-07-09 |
Family
ID=89639776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311664721.8A Active CN117462626B (en) | 2023-12-06 | 2023-12-06 | Traditional Chinese medicine composition for treating skin injury caused by rash |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117462626B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474283A (en) * | 2009-01-22 | 2009-07-08 | 郑仰一 | Chinese medicine composition for treating eczema |
| CN116549578A (en) * | 2023-06-29 | 2023-08-08 | 首都医科大学附属北京胸科医院 | Traditional Chinese medicine composition for treating adverse reaction of tumor drugs |
-
2023
- 2023-12-06 CN CN202311664721.8A patent/CN117462626B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474283A (en) * | 2009-01-22 | 2009-07-08 | 郑仰一 | Chinese medicine composition for treating eczema |
| CN116549578A (en) * | 2023-06-29 | 2023-08-08 | 首都医科大学附属北京胸科医院 | Traditional Chinese medicine composition for treating adverse reaction of tumor drugs |
Non-Patent Citations (3)
| Title |
|---|
| 朱爱茹: "苦参洗液治疗急性渗出性湿疹160例", 中国民间疗法, no. 06, 28 June 2005 (2005-06-28), pages 20 - 21 * |
| 杨人泽，等: "中西药方内服外搽治疗接触性皮炎80例疗效观察", 时珍国医国药, vol. 21, no. 11, 20 November 2010 (2010-11-20), pages 3030 * |
| 鲜馥阳，等: "中西医结合治疗重型大疱性类天疱疮病案一则", 环球中医药, vol. 13, no. 09, 6 September 2020 (2020-09-06), pages 1515 - 1518 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117462626B (en) | 2024-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012139314A1 (en) | Chinese herbal medicinal composition for treating cancer | |
| CN116549578A (en) | Traditional Chinese medicine composition for treating adverse reaction of tumor drugs | |
| CN104491766B (en) | One treats melanomatous Chinese medicine composition and preparation method thereof | |
| CN103877289A (en) | Medicine for treating breast cancer and preparation method of medicine | |
| Man et al. | Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma | |
| CN117462626B (en) | Traditional Chinese medicine composition for treating skin injury caused by rash | |
| CN101869618B (en) | Chinese medicinal acne-removal mixture for treating acne | |
| CN109125559B (en) | Traditional Chinese medicine for treating qi-yin deficiency syndrome of purpuric nephritis in children | |
| CN110787239B (en) | Traditional Chinese medicine composition for treating EGFR-TKIs (epidermal growth factor receptors-TKIs) related rashes and application thereof | |
| CN105233188A (en) | Traditional Chinese medicine composition for treating liver cancer and application of traditional Chinese medicine composition | |
| CN105521246A (en) | Medicinal preparation for treating lung cancer and applications of medicinal preparation | |
| CN111529668A (en) | Traditional Chinese medicine composition for treating herpes zoster | |
| AU2021100899A4 (en) | TCM Cataplasm for Dampness heat Acne and Its Preparation Method | |
| CN110496199B (en) | Medicine for treating psoriasis and preparation method thereof | |
| CN115245549B (en) | Traditional Chinese medicine composition for improving gouty arthritis with damp-heat constitution | |
| CN114732881B (en) | Traditional Chinese medicine composition and preparation for treating chronic perianal eczema and preparation method thereof | |
| CN116920044A (en) | Traditional Chinese medicine composition for postoperative rehabilitation of lung cancer | |
| CN113925947A (en) | Traditional Chinese medicine formula for treating liver cancer | |
| CN113876903A (en) | Traditional Chinese medicine formula for treating psoriasis by oral administration and external washing | |
| CN112717011A (en) | Traditional Chinese medicine for treating cancer | |
| CN111135252A (en) | Traditional Chinese medicine composition for adjuvant therapy of lung cancer and preparation method thereof | |
| CN117530916A (en) | External liquid medicine for treating eczema and preparation method thereof | |
| CN115779032A (en) | Traditional Chinese medicine external application preparation for treating postpartum physiological mammary swelling | |
| CN118845960A (en) | Traditional Chinese medicine composition for treating breast cancer and preparation method thereof | |
| CN115581742A (en) | A Chinese medicinal composition for treating mammary gland diseases, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |